Article info
PDFEditorial
BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk
- Correspondence to Prof Harvey D White, Green Lane Cardiovascular Research Unit, Auckland City Hospital, Auckland 1142, New Zealand; harveyw{at}adhb.govt.nz
Citation
BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk
Publication history
- First published May 4, 2022.
Online issue publication
July 27, 2022
Article Versions
- Previous version (4 May 2022).
- Previous version (11 July 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.